文献速递贫血与红细胞疾病血栓与止血

遗传性出血性毛细血管扩张症的新兴疗法综述

Emerging novel therapies for the treatment of hereditary haemorrhagic telangiectasia.
PubMed 文献 · Lancet Haematol · 2026-10-11

遗传性出血性毛细血管扩张症(HHT)是第二常见的遗传性出血性疾病,全球尚无获批疗法。本综述总结了HHT的病理生理背景,并详细讨论了针对血管和止血系统的新型在研药物,包括engasertib、ATV-1601、TER-4480、ALN-6400、DIAG723和TX2100的作用机制、治疗原理及临床试验项目。

要点

  • HHT是第二常见遗传性出血性疾病,患病率是血友病两倍以上。
  • HHT并发症包括鼻出血、消化道出血、缺铁性贫血、颅内出血和血栓栓塞等。
  • 多种靶向血管和止血系统的新药正在HHT中正式开发。

核心结论

  • HHT仍无全球获批疗法,但多种靶向血管和止血系统的新型药物正在专门开发中。

研究设计与样本

  • 这是一篇综述,检索范围未在摘要中明确说明。

主要发现

  • HHT是第二常见遗传性出血性疾病,患病率超过血友病两倍以上,且是女性最致病的遗传性出血性疾病。
  • HHT患者出现毛细血管扩张和动静脉畸形,导致中度至重度慢性鼻出血、消化道出血、缺铁性贫血及需要静脉铁剂或红细胞输注。
  • HHT颅内出血发生率高,静脉血栓栓塞、卒中和肝病等非出血性并发症常见。

关键数值与推荐

  • 新型药物包括选择性AKT1/AKT2抑制剂engasertib、AKT1选择性抑制剂ATV-1601和TER-4480、纤溶酶原siRNA药物ALN-6400、ALK1-BMPRII双特异性簇集抗体DIAG723和apelin受体拮抗剂抗体TX2100。

临床怎么用

  • 综述为HHT新药开发提供背景和机制依据,但未给出临床实践推荐。

局限性

  • 摘要未报告综述的检索范围、纳入标准或证据等级。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hereditary haemorrhagic telangiectasia is the second most common heritable bleeding disorder worldwide, with a prevalence more than twice that of haemophilia, and is the most morbid inherited bleeding disorder of women. As an autosomal dominant vasculopathy due to dysregulated angiogenic signalling, patients with hereditary haemorrhagic telangiectasia develop telangiectasias and arteriovenous malformations which cause numerous complications. These complications include moderate-to-severe chronic epistaxis, gastrointestinal bleeding, iron deficiency anemia, and requirement for intravenous iron or red cell transfusion. Additionally, incidence of intracranial haemorrhage is high and morbid non-bleeding complications, such as venous thromboembolism, stroke, and liver disease, are common. Despite this serious disease burden, hereditary haemorrhagic telangiectasia remains without licensed therapies worldwide. However, many novel, investigational agents targeting vascular and haemostatic systems are now rapidly undergoing formal development specifically in hereditary haemorrhagic telangiectasia. These agents include the selective AKT1/AKT2 inhibitor engasertib, AKT1-selective inhibitors ATV-1601 and TER-4480, plasminogen siRNA agent ALN-6400, activin receptor-like kinase 1-bone morphogenetic protein receptor type II (ALK1-BMPRII) bispecific clustering antibody DIAG723, and apelin receptor antagonist antibody TX2100. This comprehensive Review provides essential background information and illustrations summarising relevant hereditary haemorrhagic telangiectasia pathophysiology, followed by focused, detailed discussions of each of the novel agents in development, including the mechanisms, therapeutic rationale, clinical trial programmes, and potential therapeutic effects.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Al-Samkari H. Emerging novel therapies for the treatment of hereditary haemorrhagic telangiectasia. Lancet Haematol. 2026. PMID: 42860130. doi:10.1016/S2352-3026(26)00190-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。